News

A once-daily 200 mg dose of IkT-148009, Inhibikase Therapeutics‘ investigational therapy for Parkinson’s disease, reached steady levels in the body after four days without causing any serious side effects in healthy volunteers. The company plans to include this dose in its ongoing Phase 2 study (NCT05424276) in…

Abbvie is funding a clinical trial called PROSPECT to assess how clinical outcomes and disease burden change over time for people with Parkinson’s disease whose symptoms are not adequately controlled with available treatments. Interim data from the trial, presented at this year’s American Academy of Neurology (AAN) annual…

An assay using skin biopsies, called the Syn-One Test, was able to detect the alpha-synuclein protein that characterizes Parkinson’s disease and like conditions in more than 90% of the patients enrolled in a clinical trial. “These results validate cutaneous [skin-based] alpha-synuclein as a reliable biomarker for Parkinson’s disease and…

Noninvasive low-intensity focused ultrasound (LIFU) temporarily opened the blood-brain barrier to allow molecules to enter the brains of Parkinson’s disease patients, a study reports. In nonhuman primates, LIFU safely enhanced the delivery of a gene therapy model using a harmless, modified virus directly to the striatum, a region affected…

The investigational combination therapy P2B001 was similar to Mirapex (pramipexole) at controlling symptoms of Parkinson’s disease in a clinical trial. But patients treated with P2B001 were less likely to experience sleepiness and fewer had orthostatic hypotension (a sudden drop in blood pressure on standing) as side effects. Lawrence Elmer,…

IPX203, Amneal Pharmaceuticals‘ investigational extended-release carbidopa/levodopa (CD/LD) treatment for Parkinson’s disease, continued to exhibit a favorable safety and efficacy profile during the open-label extension part of the Phase 3 RISE-PD trial. “IPX203 remained as efficacious and safe as it was shown during the RISE-PD study, and the vast…

Parkinson’s disease patients treated with prasinezumab for three years — as part of a long-term extension of the Phase 2 PASADENA clinical trial — were shown to be at a lower risk of motor symptom progression and motor complications than patients who started treatment a year later, according to…

DopaFuse, a continuous oral levodopa-carbidopa delivery system, led to more stable levels of medication in the blood and better control of symptoms for people with Parkinson’s disease in a small Phase 2 study. Warren Olanow, MD, a neurologist at Mount Sinai, presented findings from the trial at the…

Most people with Parkinson’s disease treated with SPN-830, an apomorphine infusion pump, report improvement in their health status. SPN-830 also reduced “off” time, when symptoms are not being adequately controlled, by an average of about three hours a day. That’s according to new results from an open-label…

The Michael J. Fox Foundation (MJFF) has awarded a $150,000 grant to a biopharmaceutical company seeking to develop a positron emission tomography (PET) tracer for NLRP3, a therapeutic target tied to brain inflammation in Parkinson’s disease. With the funding, Ventus Therapeutics hopes to identify and develop a…